Literature DB >> 28542986

Tryptase expression as a prognostic marker in patients with resected gastric cancer.

C Lin1, H Liu1, H Zhang1, Y Cao2, R Li1, S Wu2, H Li1, H He1, J Xu2, Y Sun1.   

Abstract

BACKGROUND: Mast cells play important roles in the progression of various malignancies, but their prognostic value in gastric cancer is unknown. Tryptase expression, as an indicator of mast cell activity, was therefore evaluated to see whether this could be incorporated usefully into a prognostic nomogram after surgery in patients with gastric cancer.
METHODS: Tissue microarrays from patients with gastric cancer were created from formalin-fixed, paraffin-embedded resection specimens. Tryptase density was assessed by immunohistochemistry, and the association between tryptase expression and prognosis was evaluated. Semiquantitative scoring was devised to determine an optimal cut-off value that correlated with survival. A prognostic nomogram was then developed incorporating tryptase expression scores along with other variables known to be related to survival.
RESULTS: Tissue microarrays were generated from 419 patients having surgery for gastric cancer. Increased tryptase expression was associated with better overall and recurrence-free survival (both P < 0·001). Tryptase expression was an independent favourable prognostic factor for overall (HR 0·72; P = 0·027) and recurrence-free (HR 0·74; P = 0·044) survival. The accuracy of an established prognostic model was improved when tryptase expression was added.
CONCLUSION: Tryptase expression is an independent prognostic factor for overall and recurrence-free survival in patients with gastric cancer after surgical resection.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28542986     DOI: 10.1002/bjs.10546

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

1.  Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.

Authors:  Yipin Lv; Yongliang Zhao; Xianhua Wang; Na Chen; Fangyuan Mao; Yongsheng Teng; Tingting Wang; Liusheng Peng; Jinyu Zhang; Ping Cheng; Yugang Liu; Hui Kong; Weisan Chen; Chuanjie Hao; Bin Han; Qiang Ma; Quanming Zou; Jun Chen; Yuan Zhuang
Journal:  J Immunother Cancer       Date:  2019-02-26       Impact factor: 13.751

2.  High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer.

Authors:  Xiaobo Bo; Jie Wang; Changcheng Wang; Lingxi Nan; Zhihui Gao; Yanlei Xin; Min Li; Sheng Shen; Han Liu; Xiaoling Ni; Tao Suo; Dexiang Zhang; Pinxiang Lu; Yueqi Wang; Houbao Liu
Journal:  Cancer Sci       Date:  2020-02-03       Impact factor: 6.716

3.  Clinical and transcriptional signatures of human CD204 reveal an applicable marker for the protumor phenotype of tumor-associated macrophages in breast cancer.

Authors:  Yunjie He; Siying Zhou; Fei Deng; Shujie Zhao; Wenquan Chen; Dandan Wang; Xiu Chen; Juncheng Hou; Jian Zhang; Wei Zhang; Li Ding; Jinhai Tang; Zuomin Zhou
Journal:  Aging (Albany NY)       Date:  2019-12-04       Impact factor: 5.682

4.  Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response.

Authors:  H Fang; R Li; Y Gu; Yuchao Fei; Kaifeng Jin; Yifan Chen; Yifan Cao; Xin Liu; Kunpeng Lv; Jieti Wang; Kuan Yu; Chao Lin; Hao Liu; He Li; Hongyong He; Weijuan Zhang; Heng Zhang; Zhenbin Shen
Journal:  Oncoimmunology       Date:  2020-12-15       Impact factor: 8.110

5.  Degranulation of mast cells induced by gastric cancer-derived adrenomedullin prompts gastric cancer progression.

Authors:  Yi-Pin Lv; Liu-Sheng Peng; Qi-Hong Wang; Na Chen; Yong-Sheng Teng; Ting-Ting Wang; Fang-Yuan Mao; Jin-Yu Zhang; Ping Cheng; Yu-Gang Liu; Hui Kong; Xiao-Long Wu; Chuan-Jie Hao; Weisan Chen; Jiang Zhu; Bin Han; Qiang Ma; Ke Li; Quanming Zou; Yuan Zhuang
Journal:  Cell Death Dis       Date:  2018-10-10       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.